,9 A 6-week course of doxycycline (200 mg daily) has also been reported to be associated with reduced disease progression in lymphedema patients with or without active infection with W. bancrofti,10, –12 an observation potentially related to doxycycline’s potential role in inhibiting lymphatic endothelium-derived vascular endothelial growth factor-C and other angiopoietin-like factors involved in the pathogenesis of lymphedema.10 This evidence concerns the gene VEGFC and lymphedema.